Cagrilintide vs Survodutide
A neutral, side-by-side comparison of two glp-1 & metabolic peptides — their mechanisms, dosing ranges, administration routes, side effects, and research evidence. For research and educational purposes only.
Cagrilintide
Long-acting amylin/CGRP receptor co-agonist developed by Novo Nordisk. Reduces food intake and body weight via central satiety pathways distinct from the GLP-1 pathway. In the CagriSema combination trial with semaglutide, the combination achieved up to ~25% weight reduction — substantially greater than either agent alone.
Full profileSurvodutide
Survodutide is an investigational dual agonist of the glucagon and GLP-1 receptors, developed by Boehringer Ingelheim and Zealand Pharma. It pairs GLP-1's appetite suppression with glucagon-driven energy expenditure and hepatic fat oxidation — a mechanism especially promising for fatty-liver disease. It is not FDA-approved.
Full profile| Cagrilintide | Survodutide | |
|---|---|---|
| Category | GLP-1 & Metabolic | GLP-1 & Metabolic |
| Also known as | AM833, amylin analogue, CagriSema partner | BI 456906, Glucagon/GLP-1 dual agonist, Zealand/Boehringer dual agonist |
| Evidence | Investigational (in trials) | Investigational (in trials) |
| Dosing range | 0.3mg–2.4mg mg, once weekly subcutaneous | 0.3mg–6mg mg, once weekly subcutaneous |
| Administration | Subcutaneous injection | Subcutaneous injection (weekly) |
| Key side effects | Nausea, Vomiting, Injection site reactions, Decreased appetite | Nausea (dose-dependent, during titration), Vomiting, Diarrhea, Decreased appetite |
| Cited sources | 2 references | 2 references |
Key differences
- Administration: Cagrilintide — Subcutaneous injection; Survodutide — Subcutaneous injection (weekly).
How each works
Cagrilintide
Cagrilintide activates amylin receptors (RAMP/CTR complexes) in the area postrema and hypothalamus, reducing food intake and slowing gastric emptying through mechanisms independent of GLP-1 signaling. This non-overlapping pathway allows combination with semaglutide without compounding GI side effects. Phase 2 CagriSema data showed 15–25% weight loss at 32 weeks, supporting the complementary mechanism hypothesis.
Survodutide
Survodutide activates both the glucagon receptor (increasing energy expenditure and liver fat oxidation) and the GLP-1 receptor (reducing appetite and slowing gastric emptying). Its Phase 3 SYNCHRONIZE-1 obesity trial met its primary endpoint with meaningful weight loss at 76 weeks, and survodutide holds FDA Breakthrough Therapy designation for non-cirrhotic MASH (metabolic dysfunction-associated steatohepatitis) with moderate-to-advanced fibrosis. As of mid-2026 it remains investigational, with efficacy figures at the topline/conference stage.
This comparison aggregates public research and structured profile data for informational purposes only. It is not medical advice and does not recommend either compound for human use. Consult a qualified healthcare provider before considering any peptide.